Increasing tacrolimus time‐in‐therapeutic range is associated with superior one‐year outcomes in lung transplant recipients-Reference-Cited by-同舟云学术

Increasing tacrolimus time‐in‐therapeutic range is associated with superior one‐year outcomes in lung transplant recipients

Published:2018-04-06 Issue:6 Volume:18 Page:1527-1533
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Ensor Christopher R.¹²,Iasella Carlo J.¹,Harrigan Kate M.³,Morrell Matthew R.²,Moore Cody A.⁴,Shigemura Norihisa⁵,Zeevi Adriana⁶,McDyer John F.²,Venkataramanan Raman⁷⁶

Affiliation:

1. Department of Pharmacy and Therapeutics University of Pittsburgh School of Pharmacy Pittsburgh PA USA

2. Division of Pulmonary, Allergy, and Critical Care Medicine University of Pittsburgh School of Medicine Pittsburgh PA USA

3. Department of Pharmacy Systems, Outcomes & Policy University of Illinois at Chicago College of Pharmacy Chicago IL USA

4. Department of Pediatrics University of Pittsburgh School of Medicine Pittsburgh PA USA

5. Department of Cardiothoracic Surgery University of Pittsburgh School of Medicine Pittsburgh PA USA

6. Department of Pathology University of Pittsburgh School of Medicine Pittsburgh PA USA

7. Department of Pharmaceutical Sciences University of Pittsburgh School of Pharmacy Pittsburgh PA USA

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajt.14723

Reference20 articles.

1. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report—2015; Focus Theme: Early Graft Failure

2. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation

3. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice

4. Population Pharmacokinetic Modelling and Design of a Bayesian Estimator for Therapeutic Drug Monitoring of Tacrolimus in Lung Transplantation

5. Food and Drug Administration.Draft Guidance on Warfarin Sodium Tablet/Oral. Center for Drug Evaluation and Research.https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm201283.pdf. Accessed August 21 2017.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of CYP3A5 genotype-guided tacrolimus dosing in solid organ transplantation using real-world data;The Pharmacogenomics Journal;2024-05-15

2. Tacrolimus’s Time Below Therapeutic Range Is Associated With Acute Pancreatic Graft Rejection and the Development of De Novo Donor-specific Antibodies;Transplant International;2024-04-17

3. Tacrolimus Variability and Clinical Outcomes in the Early Post-lung Transplantation Period: Oral Versus Continuous Intravenous Administration;Clinical Pharmacokinetics;2024-04-06

4. Exploratory associations of tacrolimus exposure and clinical outcomes after lung transplantation: A retrospective, single center experience;European Journal of Clinical Pharmacology;2024-02-16

5. Erratic tacrolimus levels at 6 to 12 months post-lung transplant predicts poor outcomes;JHLT Open;2024-02